Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. - Wikidata - wikimedia - TriplyDB

Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.

Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.

http://www.wikidata.org/entity/Q31039889

about

Maximizing the Therapeutic Potential of HSP90 Inhibitors Novobiocin analogues with second-generation noviose surrogates.Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells.The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.High-throughput screen of natural product libraries for hsp90 inhibitors.Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors Arum Palaestinum with isovanillin, linolenic acid and β-sitosterol inhibits prostate cancer spheroids and reduces the growth rate of prostate tumors in mice KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90 X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response HSP90: chaperone-me-not.Targeting heat shock proteins in metastatic castration-resistant prostate cancer.Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors.A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy.Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery Alternative approaches to Hsp90 modulation for the treatment of cancer.Identification of a new scaffold for hsp90 C-terminal inhibition Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors Chemically accessible hsp90 inhibitor that does not induce a heat shock response A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response Novobiocin Analogues That Inhibit the MAPK Pathway.Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail.Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors.Dimerization of a heat shock protein 90 inhibitor enhances inhibitory activity.A chemical compound inhibiting the Aha1-Hsp90 chaperone complex.Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

P2860

Q26798318-E6A374BE-DE45-4120-9205-F2B61DEA219A Q34010496-94E27ECA-41EF-4A21-8053-AE36A1864F58 Q35017614-7755E34F-CD53-4F20-8316-C536352ECBAD Q35121121-D00D918E-2EB7-42C3-9E67-C465E8CF5D2A Q35164144-1C66C7B3-8631-4B4C-9997-9EDB2546B4B6 Q35169647-B1EB3B8E-D60F-4297-B658-24FF78880329 Q35564420-6D5A56E2-F3CA-4CF5-BB37-4F742F78045C Q35737994-F0414D68-FD5C-4393-9822-EFF1C371DF2F Q35745925-8DD42448-CF18-40CD-9A21-83C344A2A87F Q35849973-954F643E-D762-4999-8DCB-3AC95574A5CC Q36642876-F7104E37-DD69-4062-85AD-567B540272F7 Q36844176-DB59E154-B15E-4EB1-BB61-55DB2911E94F Q37293806-7D166142-98CE-4263-850C-1A79A0753C15 Q37301905-3145B05E-4693-46A4-801C-3B061C8E5024 Q38125419-58AFD361-CD73-46DF-845F-4D407751DB39 Q38289945-2573EA7C-42D9-41F8-8CA9-2BAD0C854FA1 Q38727743-F5A33EF0-C1C1-417B-AD52-40BF4A6518F7 Q38740513-0E9E7775-17E9-4859-B318-6C033620AD72 Q38750417-6C806C7B-4002-43C2-B642-FD511DE97EA3 Q38869328-4132632D-1C27-476B-B37B-1EC7B0F0251A Q39002157-114D0E48-D3AF-49C1-9779-B849870CD77F Q39031940-8C0A88D8-3A50-4969-8DAB-930FFD399318 Q39103704-F638AB26-0644-4514-92D5-333904D7D2DE Q39786880-7550891E-214F-4087-B999-547B2C063782 Q39867588-7CCCF9FD-0425-4ABA-B8BE-1F8D7438208D Q41863286-8B289A30-509A-484D-B19D-9DB139C0DD78 Q41864092-23B2C1E6-623A-425D-9396-6C5229DD8B99 Q42245370-83D44FC0-62EA-43D4-905F-923AA213F229 Q42358762-44607946-886B-45B0-81DE-8CE6447C4CBB Q42945545-1B73EA71-8C0F-422B-B424-61646E1313B6 Q45731359-42245A6F-F19F-4545-9E7B-15357BBBF8A4 Q47886847-C59A8E49-5D62-4BD2-BEB3-134032D14C34 Q48118580-22B2A109-3444-44D9-8429-F314E9B0CFFA Q53808764-B7AC45AE-C500-4F5F-9B66-71B29DAACB6B

P2860

Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.

http://www.wikidata.org/entity/Q31039889

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Development and characterizati ...... pendent prostate cancer cells.

@ast

Development and characterizati ...... pendent prostate cancer cells.

@en

type

label

Development and characterizati ...... pendent prostate cancer cells.

@ast

Development and characterizati ...... pendent prostate cancer cells.

@en

prefLabel

Development and characterizati ...... pendent prostate cancer cells.

@ast

Development and characterizati ...... pendent prostate cancer cells.

@en

P1433

Q31039889-D806D280-7E25-4234-A0C7-EB909E28C4AD

P1476

Q31039889-D2861CFE-AD65-4421-9598-48B4E0463F99

P2093

Q31039889-03C5C2E6-14AA-4199-B9D0-034934202DBD

Q31039889-0F22E619-8329-41D9-8718-CC02483E605A

Q31039889-1F47A312-EDF2-4B5F-A25A-3C6B1FC2DBDC

Q31039889-32393F5B-A373-4CC6-B751-4C1F45FDAA31

Q31039889-3EA7DDD1-6800-423F-B23A-D042059DF271

Q31039889-6BCDDB15-AFDB-42F0-ADFC-1FA2114BDE1A

Q31039889-7A4F2FCB-1152-4946-9CF9-0EA4AF103A5D

Q31039889-89D7608A-AEA1-465D-B6DA-8CA097707FFB

Q31039889-94CAF42F-2CCD-4DB5-9FCC-4CC395EEC980

Q31039889-96D7D736-407A-48CB-9E16-30C56900B8DC

P2860

Q31039889-006027DD-3273-46F1-B0DD-83056FB61642

Q31039889-00BE03BD-AB29-4549-95C3-5B1BC82D438D

Q31039889-0F8A99E9-59FB-4B80-991A-1DC835202E0B

Q31039889-2736E7C4-932D-4A39-8DBF-3EBA54D73363

Q31039889-38F62808-5D6C-4E24-9D75-B3A0BF3DDEC3

Q31039889-48481738-0BD5-4926-AF17-BCBC9D460EA9

Q31039889-4D8523FC-D82A-440B-84E9-C71B7A1B014E

Q31039889-52D6DDEC-D6CB-417E-AA9E-1E8B28D33A33

Q31039889-536A76D6-470B-4EFF-A9AF-19E2A15CEDB3

Q31039889-5A5F367C-7DEB-485C-9DD8-95C7CF94C3E8

P2888

Q31039889-AE23B6FE-9A35-489C-8A59-4E910C74BF2B

P304

Q31039889-39232B56-C6DA-469C-BAFF-512A7CE89F23

P31

Q31039889-2B8A19C7-7D9B-4C55-ABAF-67F41FACB817

P356

Q31039889-35DCCD2D-3AB5-44A8-93F0-C8482D7896BC

P407

Q31039889-6B2C3F74-1B66-4EF4-BD6B-2848FD2581C6

P478

Q31039889-F7B8EA60-0BAD-4073-8AE8-587DA5D3BB21

P577

Q31039889-CD25AFE0-9485-44E4-A222-6E05AA6AD14F

P5875

Q31039889-03BD7382-73E7-4590-8530-2A347B14E60E

P6179

Q31039889-84CC4376-AE90-435D-B927-B5585ADF6B4C

P698

Q31039889-BE71BB25-80D5-465A-A41F-43A0FEE7CD96

P932

Q31039889-8FE4DDF6-55F5-46D4-9478-72AC123F4863

P356

1471-2407-11-468

P1433

P1476

Development and characterizati ...... pendent prostate cancer cells.

@en

P2093

Alicia Duren

http://www.w3.org/2001/XMLSchema#string

Alison Donnelly

http://www.w3.org/2001/XMLSchema#string

Brian S J Blagg

http://www.w3.org/2001/XMLSchema#string

George A Vielhauer

http://www.w3.org/2001/XMLSchema#string

Irene Dunwiddie

http://www.w3.org/2001/XMLSchema#string

Jacob R Manjarrez

http://www.w3.org/2001/XMLSchema#string

Jeffery D Eskew

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Holzbeierlein

http://www.w3.org/2001/XMLSchema#string

Megan Swink

http://www.w3.org/2001/XMLSchema#string

Pedro Morales

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of direct protein targets of small molecules

Pulse proteolysis: A simple method for quantitative determination of protein stability and ligand binding

Short tandem repeat profiling provides an international reference standard for human cell lines

Hsp90 inhibitors identified from a library of novobiocin analogues.

Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.

A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice.

Recognition sequences of repressor and polymerase in the operators of bacteriophage lambda.

Hsp90 inhibitors as novel cancer chemotherapeutic agents.

P2888

1471-2407-11-468

P304

468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-468

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51757322

http://www.w3.org/2001/XMLSchema#string

P6179

1033320680

http://www.w3.org/2001/XMLSchema#string

P698

22039910

http://www.w3.org/2001/XMLSchema#string

P932

3240935

http://www.w3.org/2001/XMLSchema#string